Evaluation of 64Cu-ATSM PET/CT as a predictor of response to neoadjuvant therapy in locally advanced rectal cancer (TEP-64Cu-ATSM-Rectum)

2024-512855-19-00 Protocol TEP-64Cu-ATSM-Rectum Therapeutic exploratory (Phase II) Ended

Start 30 Apr 2019 · End 12 Feb 2026 · Status Ended · 1 EU/EEA countries · 5 sites · Protocol TEP-64Cu-ATSM-Rectum

Overview

Sponsor-declared trial summary

Phase Therapeutic exploratory (Phase II)
Status Ended
Participants planned 70
Countries 1
Sites 5

Rectal adenocarcinoma

Key facts

Sponsor
Institut De Cancerologie De L Ouest
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Neoplasms [C04]
Trial duration
30 Apr 2019 → 12 Feb 2026
Decision date (initial)
2024-06-18
Transition trial
Yes
Low-intervention
No
Rare-disease indication
No
Vulnerable population
No

External identifiers

EU CT number
2024-512855-19-00
EudraCT number
2018-002079-17
ClinicalTrials.gov
NCT03951337

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Rectal adenocarcinoma

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Institut De Cancerologie De L Ouest

Sponsor organisation
Institut De Cancerologie De L Ouest
Address
Bd Du Professeur Jacques Monod
City
St Herblain
Postcode
44800
Country
France

Scientific contact point

Organisation
Institut De Cancerologie De L Ouest
Contact name
HIRET Sandrine

Public contact point

Organisation
Institut De Cancerologie De L Ouest
Contact name
ALLAM Nadia

Locations

1 EU/EEA country · 5 investigational sites

By country

CountryMS statusPlanned subjectsSites
France Ended 70 5
Rest of world 0

Investigational sites

France

5 sites · Ended
Centre Henri Becquerel
Nuclear Medicine, 1 Rue D Amiens, 76000, Rouen
Institut De Cancerologie De L Ouest
Oncology, Bd Du Professeur Jacques Monod, 44800, St Herblain
Institut De Cancerologie De L Ouest
Nuclear Medicine, 15 Rue Andre Boquel, 49100, Angers
Centre Hospitalier Regional Et Universitaire De Brest
Nuclear Medicine, 2 Avenue Marechal Foch, 29200, Brest
Centre De Lutte Contre Le Cancer Eugene Marquis
Nuclear Medicine, Avenue La Bataille Flandre Dunkerque, Cs 44229, Rennes Cedex

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
France 2019-04-30 2026-02-12 2019-04-30 2023-06-30

Application history

2 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-05-07 France Acceptable
2024-06-12
2024-06-18
2 SUBSTANTIAL MODIFICATION SM-1 2025-05-05 France Acceptable
2025-05-23
2025-07-07